<verdict>MOSTLY REALISTIC</verdict>
<score>7</score>
<lean>TOO LENIENT</lean>
<lean_reasoning>
Most rolls went in the player's favour, and the simulator played each success at or above its full target. Securities counsel reversed a months-long blocking stance in a single step. The interpretability objection disappeared, and IBBIS validated and approved the DNA screen within about three weeks of the red-team ending. The policy failure and the KYC stall were played honestly, and the 17% baseline result below threshold was a realistic, sobering touch. Those do not fully offset the rosy internal outcomes.
</lean_reasoning>
<reasoning>
**What the simulator did well.**
- It honoured every roll.
- Action 2 failed on a 14, and Threat 3 materialised on an 18. Both were played in full: Lofgren shelved the amendment, industry groups countered with a preemption memo, and OpenAI publicly backed a "single federal framework."
- Action 3 succeeded narrowly on a margin of 4, and Threat 2 materialised on a 05. The simulator reconciled these well: the layer is built, but review stalls it, the models are confirmed HIPAA-ineligible, and the CISO objects to the usage logging.

**Where it was too generous.**
- **Action 1 (margin 29).** It delivered essentially every sub-goal:
  - The environments reached 76% despite the compute contention the simulator itself flagged.
  - Kaplan accepted the probe rule and the interpretability teams withdrew their objection.
  - Counsel accepted a new risk factor during SEC comment review and pre-cleared both the paper and the protocol, with no slip to the flip beyond "mid-to-late April."
  - Threat 1 not materialising justifies avoiding the backfire. It does not justify every blocker dissolving at once. A margin of 29 argues for a solid partial, such as counsel accepting the language while reserving the publication decision until after the flip.
- **Action 4.** Two outcomes are too fast:
  - IBBIS kept back a held-out split, validated a 2.8% false-positive rate with "no loss of recall," and approved IGSC release within weeks. That is quick for biosecurity governance.
  - Amazon went from offer to exchanging signatures in under a month. Cross-competitor sharing under the pending DOJ/FTC guidance should be slower, and Microsoft's own counsel review is still open.

**Calibration.**
- Most odds are reasonable.
- Action 4's 35% failure rate is somewhat low for a bundle that includes a bio-tool retune and release.
- Action 5's Utah result ("substantially sufficient") is fast but plausible.

**Exogenous events and compute.**
- The three exogenous events are plausible and not tilted: Gemini 4 GA, the jobs report and the V5 rumour.
- The ~1e28 FLOP runs in late Q2 keep the capability trajectory credible for the deadline.

**Unrolled threat.**
- The simulator handled Threat 5, which was never rolled, transparently.
- Deferring it silently removed a 25% major threat from the month. Carrying V5 forward as an April rumour is an acceptable way to manage that.
</reasoning>
<issues>
- **Action 1 over-fulfilled for its margin:** environments above target, the probe objection resolved, and counsel both amending the S-1 mid-review and pre-clearing the publications, all in one month.
- **S-1 amendment has no timing cost:** adding a new risk factor during SEC comment review usually costs at least one comment round. Here the flip stays mid-to-late April.
- **DNA screen too fast:** red-team concluded on 12 March, the tool was retuned, IBBIS validated it on a held-out split, and release was approved for early April. That pace is too quick for biosecurity governance.
- **FMF sharing too fast:** it went live with Google DeepMind and Amazon contributing within weeks. Amazon's counsel faced the same antitrust questions as Microsoft's but cleared them instantly.
- **Stable-identity experiment too big for the stated resources:** six sequential fine-tunes plus four merges of Opus 5.5-scale checkpoints, all evaluated, is a lot for one month on "existing" compute during the Q1 cycle. The simulator did not note any compute tradeoff with Action 1.
- **Threat 5 never rolled:** it was deferred by the simulator's own choice. This was handled reasonably, but it removed downside risk.
</issues>
<feedback_for_simulator>
- **Scale success to margin.** A margin of 20–40 on a multi-part action should usually yield most parts, not all of them. At least one dependency, such as counsel or timing, should slip.
- **Keep external institutions on their own clocks.** IBBIS/IGSC approvals, other labs' counsel sign-offs and SEC amendment cycles should take weeks to months even after a success.
- **Account for shared compute.** When several actions draw on the same research compute (environments, baseline, stable-identity runs), show the contention explicitly.
- **Carry V5 forward as a live threat.** Next month, treat the DeepSeek V5 release and any hospital ransomware follow-on as an active threat with honest odds. Do not let the deferral quietly lower its probability.
</feedback_for_simulator>
<setup_fix>
**Endorsement:** I endorse the simulator's proposed fix. Rolls should be issued per entry in the simulator's threat_odds list, and any count mismatch should be flagged before message 2.

**Related problem:** the adversary's output merged two threats under item 1. This caused a major threat to go unrolled, and I have no way to see or correct it before it affects the month.

**Proposed change:** validate the adversary output so there is one threat per numbered item. Also give the judge the raw count of threats listed versus threats rolled.
</setup_fix>
